![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.
Lead Product(s): Glucose Responsive Insulin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,000.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 14, 2021